Literature DB >> 17208556

Neuroblastoma-derived secretory protein messenger RNA levels correlate with high-risk neuroblastoma.

Sanjeev A Vasudevan1, Heidi V Russell, M Fatih Okcu, Susan M Burlingame, Zhiyun J Liu, Jianhua Yang, Jed G Nuchtern.   

Abstract

BACKGROUND/
PURPOSE: In advanced-stage neuroblastoma, bulky disease and systemic dissemination can be controlled with intense surgical and medical therapies; however, recurrence rates are very high in this group indicating that residual disease is rarely eradicated. The need to detect residual disease and predict prognosis is critical to planning appropriate treatment regimens for these patients. Recently, neuroblastoma-derived secretory protein (NDSP) was identified and cloned from neuroblastoma.
METHODS: Using quantitative real-time PCR, we tested NDSP messenger RNA (mRNA) expression in 45 neuroblastoma tumor samples and 5 bone marrow samples. Correlation between NDSP expression and age at diagnosis, International Neuroblastoma Staging System, MYCN amplification, and Children's Oncology Group risk stratification was analyzed using Spearman nonparametric correlation.
RESULTS: Neuroblastoma tissue samples show much higher NDSP mRNA levels above control in 43 of 45 samples (96%); moreover, these levels correlate with the Children's Oncology Group neuroblastoma risk group assignment. We also found that bone marrow samples with known tumor infiltration had much higher NDSP mRNA levels than bone marrow from patients without metastasis.
CONCLUSION: From these data, we conclude that NDSP mRNA levels in neuroblastoma tumor tissue correlate with risk group assignment and may serve as a marker for metastasis in bone marrow.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17208556     DOI: 10.1016/j.jpedsurg.2006.09.064

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  7 in total

1.  Presence of 1q gain and absence of 7p gain are new predictors of local or metastatic relapse in localized resectable neuroblastoma.

Authors:  Annalisa Pezzolo; Elena Rossi; Stefania Gimelli; Federica Parodi; Francesca Negri; Massimo Conte; Angela Pistorio; Angela Sementa; Vito Pistoia; Orsetta Zuffardi; Claudio Gambini
Journal:  Neuro Oncol       Date:  2008-10-15       Impact factor: 12.300

2.  The role of DNA methylation in human trophoblast differentiation.

Authors:  Teena K J B Gamage; William Schierding; Daniel Hurley; Peter Tsai; Jackie L Ludgate; Chandrakanth Bhoothpur; Lawrence W Chamley; Robert J Weeks; Erin C Macaulay; Joanna L James
Journal:  Epigenetics       Date:  2018-12-05       Impact factor: 4.528

3.  Neuroblastoma-derived secretory protein is a novel secreted factor overexpressed in neuroblastoma.

Authors:  Sanjeev A Vasudevan; Xiaoying Shang; Xiaoyi Shang; Shirong Chang; Ningling Ge; Jose L Diaz-Miron; Heidi V Russell; M John Hicks; Andrew D Ludwig; Catherine L Wesson; Susan M Burlingame; Eugene S Kim; Javed Khan; Jianhua Yang; Jed G Nuchtern
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

4.  Genome-wide linkage and association analysis of cardiometabolic phenotypes in Hispanic Americans.

Authors:  Jacklyn N Hellwege; Nicholette D Palmer; Latchezar Dimitrov; Jacob M Keaton; Keri L Tabb; Satria Sajuthi; Kent D Taylor; Maggie C Y Ng; Elizabeth K Speliotes; Gregory A Hawkins; Jirong Long; Yii-Der Ida Chen; Carlos Lorenzo; Jill M Norris; Jerome I Rotter; Carl D Langefeld; Lynne E Wagenknecht; Donald W Bowden
Journal:  J Hum Genet       Date:  2016-08-18       Impact factor: 3.172

5.  Identification of an eight-gene signature for survival prediction for patients with hepatocellular carcinoma based on integrated bioinformatics analysis.

Authors:  Guo-Jie Qiao; Liang Chen; Jin-Cai Wu; Zhou-Ri Li
Journal:  PeerJ       Date:  2019-03-20       Impact factor: 2.984

6.  BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting super-enhancers in neuroblastoma.

Authors:  Yan-Ling Chen; Xiao-Lu Li; Gen Li; Yan-Fang Tao; Ran Zhuo; Hai-Bo Cao; Wan-Yan Jiao; Zhi-Heng Li; Zhen-Hong Zhu; Fang Fang; Yi Xie; Xin-Mei Liao; Di Wu; Hai-Rong Wang; Juan-Juan Yu; Si-Qi Jia; Yang Yang; Chen-Xi Feng; Peng-Cheng Yang; Xiao-Dong Fei; Jian-Wei Wang; Yun-Yun Xu; Guang-Hui Qian; Zi-Mu Zhang; Jian Pan
Journal:  Cell Biosci       Date:  2022-03-18       Impact factor: 7.133

7.  FAM163A, a positive regulator of ERK signaling pathway, interacts with 14-3-3β and promotes cell proliferation in squamous cell lung carcinoma.

Authors:  Nan Liu; Haijing Zhou; Xiupeng Zhang; Lin Cai; Jingduo Li; Jing Zhao; Yang Liu; Liang Wang; Chuifeng Fan; Ailin Li; Yuan Miao
Journal:  Onco Targets Ther       Date:  2019-08-13       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.